{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T17:48:24Z","timestamp":1764784104972,"version":"3.37.3"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["7162134"],"award-info":[{"award-number":["7162134"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.bcp.2018.07.035","type":"journal-article","created":{"date-parts":[[2018,7,29]],"date-time":"2018-07-29T00:10:22Z","timestamp":1532823022000},"page":"510-523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["TGF3L fusion enhances the antitumor activity of TRAIL by promoting assembly into polymers"],"prefix":"10.1016","volume":"155","author":[{"given":"Yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cangjie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2018.07.035_b0005","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis","volume":"3","author":"Wiley","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2018.07.035_b0010","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1083\/jcb.137.1.221","article-title":"Interleukin 1 beta-converting enzyme related proteases\/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells","volume":"137","author":"Mariani","year":"1997","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2018.07.035_b0015","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrc.2017.28","article-title":"Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy","volume":"17","author":"von Karstedt","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2018.07.035_b0020","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.molcel.2012.05.004","article-title":"A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death","volume":"47","author":"Dickens","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2018.07.035_b0025","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.neo.7900270","article-title":"Defining characteristics of Types I and II apoptotic cells in response to TRAIL","volume":"4","author":"Ozoren","year":"2002","journal-title":"Neoplasia"},{"key":"10.1016\/j.bcp.2018.07.035_b0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0014-5793(00)02042-1","article-title":"Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types","volume":"482","author":"Zhang","year":"2000","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcp.2018.07.035_b0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.pharmthera.2015.09.001","article-title":"Therapeutic applications of TRAIL receptor agonists in cancer and beyond","volume":"155","author":"Amarante-Mendes","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2018.07.035_b0040","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1006\/mthe.2001.0280","article-title":"Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein","volume":"3","author":"Wu","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2018.07.035_b0045","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/j.molimm.2009.03.004","article-title":"Trimeric coiled-coil domain of human pulmonary surfactant protein D enhances zinc-binding ability and biologic activity of soluble TRAIL","volume":"46","author":"Wu","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bcp.2018.07.035_b0050","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1021\/bi992242l","article-title":"A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L\/TRAIL","volume":"39","author":"Hymowitz","year":"2000","journal-title":"Biochemistry-US"},{"key":"10.1016\/j.bcp.2018.07.035_b0055","doi-asserted-by":"crossref","first-page":"10025","DOI":"10.1074\/jbc.M413673200","volume":"280","author":"Bremer","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.07.035_b0060","first-page":"1229","article-title":"Target cell-restricted apoptosis induction by 528scFv-TRAIL fusion protein specific for human EGFR and expressed in Escherichia coli","volume":"36","author":"Badran","year":"2010","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bcp.2018.07.035_b0065","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.29","article-title":"Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity","volume":"3","author":"Siegemund","year":"2012","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2018.07.035_b0070","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.6320373","article-title":"Rat transforming growth factor type 1: structure and relation to epidermal growth factor","volume":"223","author":"Marquardt","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.bcp.2018.07.035_b0075","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/0006-291X(85)91426-3","article-title":"A synthetic fragment of rat transforming growth factor alpha with receptor binding and antigenic properties","volume":"129","author":"Nestor","year":"1985","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2018.07.035_b0080","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/318663a0","article-title":"Epidermal growth factor receptor occupancy inhibits vaccinia virus infection","volume":"318","author":"Eppstein","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.07.035_b0085","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/bjc.1998.593","article-title":"Inhibition by transforming growth factor (34\u201343)-alpha, a TGF-alpha antagonist, of gastric carcinogenesis induced by N-methyl-N\u2032-nitro-N-nitrosoguanidine in Wistar rats","volume":"78","author":"Tatsuta","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2018.07.035_b0090","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jcb.240360404","article-title":"Assessment of biological activity of synthetic fragments of transforming growth factor-alpha","volume":"36","author":"Darlak","year":"1988","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bcp.2018.07.035_b0095","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1128\/MCB.8.8.2999","article-title":"Structure-function analysis of synthetic and recombinant derivatives of transforming growth factor alpha","volume":"8","author":"Defeo-Jones","year":"1988","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bcp.2018.07.035_b0100","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/jcp.1041410224","article-title":"Inhibition of epidermal growth factor\/transforming growth factor-alpha-stimulated cell growth by a synthetic peptide","volume":"141","author":"Eppstein","year":"1989","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bcp.2018.07.035_b0105","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1399-3011.1991.tb01430.x","article-title":"Mapping the receptor-recognition site of human transforming growth factor-alpha","volume":"38","author":"Tam","year":"1991","journal-title":"Int. J. Pept. Protein Res."},{"key":"10.1016\/j.bcp.2018.07.035_b0110","first-page":"471","article-title":"Alpha-transforming growth factor: biological activity and structure-activity relationships","volume":"29","author":"Tam","year":"1986","journal-title":"Proc. West Pharmacol. Soc."},{"key":"10.1016\/j.bcp.2018.07.035_b0115","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1399-3011.1992.tb01451.x","article-title":"Efficient approach to synthesis of two-chain asymmetric cysteine analogs of receptor-binding region of transforming growth factor-alpha","volume":"39","author":"Tam","year":"1992","journal-title":"Int. J. Pept. Protein Res."},{"key":"10.1016\/j.bcp.2018.07.035_b0120","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/08977199409010997","article-title":"Structure-function relationships for the EGF\/TGF-alpha family of mitogens","volume":"11","author":"Groenen","year":"1994","journal-title":"Growth Factors"},{"key":"10.1016\/j.bcp.2018.07.035_b0125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1472-6750-10-91","article-title":"Human TGFalpha-derived peptide TGFalphaL3 fused with superantigen for immunotherapy of EGFR-expressing tumours","volume":"10","author":"Xu","year":"2010","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.bcp.2018.07.035_b0130","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/1533034614568753","article-title":"Preparation and in vitro evaluation of antitumor activity of TGFalphaL3-SEB as a ligand-targeted superantigen","volume":"15","author":"Yousefi","year":"2016","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2018.07.035_b0135","first-page":"513","article-title":"Construction and expression of hTNFalpha-hTGF3 fused gene","volume":"31","author":"Chen","year":"1999","journal-title":"Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai)"},{"key":"10.1016\/j.bcp.2018.07.035_b0140","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1023\/B:BILE.0000007072.56577.0c","article-title":"Refolding and purification of Apo2l\/TRAIL produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli","volume":"25","author":"Shen","year":"2003","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.bcp.2018.07.035_b0145","doi-asserted-by":"crossref","first-page":"11937","DOI":"10.1073\/pnas.0904191106","article-title":"Design of therapeutic proteins with enhanced stability","volume":"106","author":"Chennamsetty","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2018.07.035_b0150","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/ijc.24074","article-title":"Antitumor effects of a novel sulfur-containing hydroxamate histone deacetylase inhibitor H40","volume":"124","author":"Long","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2018.07.035_b0155","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1259\/bjr\/54004230","article-title":"Resazurin assay of radiation response in cultured cells","volume":"78","author":"Anoopkumar-Dukie","year":"2005","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.bcp.2018.07.035_b0160","doi-asserted-by":"crossref","first-page":"35000","DOI":"10.1074\/jbc.273.52.35000","article-title":"Endocytosis of functional epidermal growth factor receptor-green fluorescent protein chimera","volume":"273","author":"Carter","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.07.035_b0165","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pep.2017.06.019","article-title":"Insulin chains as efficient fusion tags for prokaryotic expression of short peptides","volume":"138","author":"Deng","year":"2017","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.bcp.2018.07.035_b0170","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.07.035_b0175","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pep.2016.02.015","article-title":"TRAIL-CM4 fusion protein shows in vitro antibacterial activity and a stronger antitumor activity than solo TRAIL protein","volume":"122","author":"Sang","year":"2016","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.bcp.2018.07.035_b0180","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.cdd.4401649","article-title":"Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1","volume":"12","author":"MacFarlane","year":"2005","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcp.2018.07.035_b0185","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1089\/hum.2015.015","article-title":"Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fiber knob domain and their evaluation as targeted cancer therapies","volume":"26","author":"Uusi-Kerttula","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bcp.2018.07.035_b0190","first-page":"74","article-title":"Location of EGFP tag affects the binding activity of peptide fusions","volume":"32","author":"Wang","year":"2012","journal-title":"China Biotechnol."},{"key":"10.1016\/j.bcp.2018.07.035_b0195","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/nm1627","article-title":"Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L\/TRAIL","volume":"13","author":"Wagner","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2018.07.035_b0200","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1038\/srep03565","article-title":"Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy","volume":"3","author":"Qiu","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2018.07.035_b0205","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s10529-007-9446-y","article-title":"Overexpression and refolding of thioredoxin\/TRAIL fusion from inclusion bodies and further purification of TRAIL after cleavage by enteropeptidase","volume":"29","author":"Gasparian","year":"2007","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.bcp.2018.07.035_b0210","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.177","article-title":"Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity","volume":"7","author":"Yan","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2018.07.035_b0215","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-immunol-042617-053010","article-title":"Apoptosis and clearance of apoptotic cells","volume":"36","author":"Nagata","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bcp.2018.07.035_b0220","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1083\/jcb.148.6.1239","article-title":"Active caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in TRAIL-induced apoptosis","volume":"148","author":"MacFarlane","year":"2000","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2018.07.035_b0225","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1097-2765(02)00482-3","article-title":"Mechanisms of caspase activation and inhibition during apoptosis","volume":"9","author":"Shi","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2018.07.035_b0230","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2407-11-39","article-title":"Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5","volume":"11","author":"van Geelen","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2018.07.035_b0235","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1196\/annals.1352.018","article-title":"TRAIL (TNF-related apoptosis-inducing ligand) induces necrosis-like cell death in tumor cells at acidic extracellular pH","volume":"1056","author":"Meurette","year":"2005","journal-title":"Ann. NY. Acad. Sci."},{"key":"10.1016\/j.bcp.2018.07.035_b0240","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.pep.2015.09.007","article-title":"Efficient refolding of the bifunctional therapeutic fusion protein VAS-TRAIL by a triple agent solution","volume":"125","author":"Fan","year":"2016","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.bcp.2018.07.035_b0245","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1158\/1535-7163.MCT-13-0645","article-title":"Immunoglobulin Fc domain fusion to TRAIL significantly prolongs its plasma half-life and enhances its antitumor activity","volume":"13","author":"Wang","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2018.07.035_b0250","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11523-016-0424-y","article-title":"Novel TNF-related apoptotic-inducing ligand-based immunotoxin for therapeutic targeting of CD25 positive leukemia","volume":"11","author":"Madhumathi","year":"2016","journal-title":"Target Oncol."},{"key":"10.1016\/j.bcp.2018.07.035_b0255","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1158\/0008-5472.CAN-04-0408","article-title":"Apo2 ligand\/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival","volume":"64","author":"Jin","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2018.07.035_b0260","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2016.03.004","article-title":"Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL","volume":"228","author":"Li","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2018.07.035_b0265","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.leukres.2015.03.019","article-title":"Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells","volume":"39","author":"De Miguel","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcp.2018.07.035_b0270","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.canlet.2017.04.026","article-title":"Fn14.TRAIL fusion protein is oligomerized by TWEAK into a superefficient TRAIL analog","volume":"400","author":"Prigozhina","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2018.07.035_b0275","doi-asserted-by":"crossref","first-page":"32208","DOI":"10.1074\/jbc.M000482200","article-title":"The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation","volume":"275","author":"Muhlenbeck","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.07.035_b0280","doi-asserted-by":"crossref","first-page":"41904","DOI":"10.1038\/srep41904","article-title":"Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle","volume":"7","author":"Huang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2018.07.035_b0285","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86397","article-title":"Differential hepatocyte toxicity of recombinant Apo2L\/TRAIL versions","volume":"7","author":"Lawrence","year":"2001","journal-title":"Nat. Med."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218303034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218303034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T04:18:59Z","timestamp":1576815539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218303034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":57,"alternative-id":["S0006295218303034"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.07.035","relation":{},"ISSN":["0006-2952"],"issn-type":[{"type":"print","value":"0006-2952"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TGF3L fusion enhances the antitumor activity of TRAIL by promoting assembly into polymers","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}